Search

Displaying results 5991 - 6000 of 10000 in total
  1. Drug

    Vibriolysin

    go.drugbank.com/drugs/DB05135
    Experimental

    Vibriolysin is a proteolytic enzyme secreted by the marine microorganism Vibrio proteolyticus. … It is a new agent for enzymatic debridement, shown to rapidly and thoroughly hydrolyze burn wound eschar within full-thickness wounds.

  2. Drug

    CR002

    go.drugbank.com/drugs/DB05139
    Investigational

    CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. … This is a novel therapeutic approach to treat kidney inflammation.

    Synonyms: Human monoclonal antibody against platelet-derived growth factor D
  3. Drug

    Lexibulin

    go.drugbank.com/drugs/DB05147
    Investigational

    CYT997 is an orally available vascular targeting and cytotoxic agent that has proven effective in animal models of a wide range of tumour types including breast, prostate and colon, as well as some leukemias

    Categories: Heterocyclic Compounds, 1-Ring
  4. Drug

    Topsalysin

    go.drugbank.com/drugs/DB05160
    Investigational

    Topsalysin is being developed for the treatment of localized prostate cancer and also benign prostatic hyperplasia. Topsalysin is delivered locally to the prostate under ultrasound guidance.

  5. Drug

    CMLVAX100

    go.drugbank.com/drugs/DB05164
    Experimental

    It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial. … CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia.

  6. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. … LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.

  7. Drug

    AT3022

    go.drugbank.com/drugs/DB05172
    Experimental

    AT3022, the Altea Therapeutics’s fentanyl citrate transdermal patch designed to provide safe and rapid management of moderate to severe chronic pain.

  8. Drug

    LX6171

    go.drugbank.com/drugs/DB05180
    Investigational

    LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia.

  9. Drug

    AS1409

    go.drugbank.com/drugs/DB05182
    Investigational

    It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma. … AS1409 is a genetically engineered fusion protein made up of two distinct components. One is the cytokine IL12, which has anti-cancer activity. The other is an antibody that targets tumours.

  10. Drug

    Olesoxime

    go.drugbank.com/drugs/DB05185
    Investigational

    Olesoxime is a cholesterol-like small molecule that has demonstrated a remarkable neuroprotective profile in a battery of both in vitro and in vivo preclinical models.

    Synonyms: (EZ)-N-(CHOLEST-4-EN-3-YLIDENE)HYDROXYLAMINE, 4-Cholesten-3-one, oxime